Ariel Investments, an investment management company, released its “Ariel Global Fund” fourth-quarter 2024 investor letter. A ...

BofA raised the firm’s price target on AbbVie (ABBV) to $223 from $200 and keeps a Neutral rating on the shares after the company and Gubra ...

DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...

We recently compiled a list of the 15 Best S&P 500 Dividend Stocks to Buy Now. In this article, we are going to take a look ...

Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with ...

Growth and income investors who want to stay invested but shift to a more balanced approach may want to look at the Dividend ...

This was the stock's third consecutive day of gains.

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ...

AbbVie Inc. (NYSE:ABBV – Get Free Report) shares hit a new 52-week high on Friday . The company traded as high as $207.42 and ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...